Patient experience with transition between intravenous infusion pumps

<bold>Background:</bold> Epoprostenol, used to treat patients with pulmonary arterial hypertension has a short half-life. It needs continuous intravenous infusion via central line and patients need to be self-caring with the infusion pump. Due to discontinuation, from May to November 2023, we upgraded the infusion pumps (CADD Legacy™ to Solis™). Patients were offered a video consultation, face-to-face training, written materials, and support from specialist nurses. <bold>Aims and Objectives:</bold> Patient feedback is important in improving care, so we assessed how they experienced and adjusted to the new pump. <bold>Methods:</bold> Anonymised questionnaires with open and closed questions, created with patient input, were sent to the transitioned patients in December 2023 (n = 24). <bold>Results:</bold> 14 questionnaires were returned (response rate 58%). 12 patients rated the transition process 4 or 5 in terms of satisfaction, 1 patient rated it 3 and another did not answer (scale 1-5, where 1 is poor and 5 is excellent). All patients felt the new pump was easier to use, 9 felt it was safer and easier to troubleshoot, whilst 5 neither agreed nor disagreed. 5 patients preferred the old pump, whilst 5 preferred the new one and 4 patients did not have a strong preference. Most patients highlighted that the new pump was heavier and larger, but also more informative and interactive. <bold>Conclusions:</bold> Overall, the pump transition was well-received with 92% of patients rating the process good or excellent. Although the new pump is heavier and larger, patients felt it was more informative and interactive. We will continue to evaluate patient feedback and long-term impact on quality of life, hospital visits, travelling and nursing time.